Pine Valley Investments Ltd Liability Co Purchases 1,272 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pine Valley Investments Ltd Liability Co increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,431 shares of the medical research company’s stock after acquiring an additional 1,272 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in IQVIA were worth $1,994,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Hantz Financial Services Inc. purchased a new stake in IQVIA during the second quarter valued at approximately $187,000. International Assets Investment Management LLC purchased a new position in IQVIA in the 2nd quarter worth approximately $32,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in IQVIA by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 46,895 shares of the medical research company’s stock valued at $9,915,000 after buying an additional 371 shares in the last quarter. Boston Financial Mangement LLC raised its position in shares of IQVIA by 13.5% during the second quarter. Boston Financial Mangement LLC now owns 7,317 shares of the medical research company’s stock valued at $1,547,000 after buying an additional 873 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in shares of IQVIA by 1.6% in the second quarter. Crossmark Global Holdings Inc. now owns 12,319 shares of the medical research company’s stock worth $2,604,000 after buying an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on IQV shares. JPMorgan Chase & Co. raised their target price on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. The Goldman Sachs Group assumed coverage on IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price on the stock. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley upped their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Finally, Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $265.67.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $251.55 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a market capitalization of $45.86 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 2.37 and a beta of 1.49. The firm’s 50-day moving average is $231.33 and its 200 day moving average is $234.20.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the firm posted $2.22 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Research analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.